Whistleblower Law Blog

Novartis and U.S. Attorney’s Office Settle FCA and Criminal Allegations Regarding Trileptal® for $422.5 Million

Novartis Pharmaceuticals reached a settlement agreement totaling $422.5 million with the U.S. Attorney’s Office for the Eastern District of Pennsylvania regarding civil allegations under the False Claims Act and criminal allegations under the Food, Drug, and Cosmetic Act relating to its misbranding of Trileptal®.

Tagged: ,

decorative line